IndraLab

Statements


4 | 1 2

No evidence text available

No evidence text available

No evidence text available

No evidence text available

reach
"MYSM1 physically associates with ERalpha in breast cancer cells."

sparser
"Virtual screening identified Imatinib as a small molecule capable of interacting with the catalytic MPN domain of MYSM1, and this effectively inhibited breast cancer cell growth, highlighting the MYSM1-ERα axis as a promising target to overcome endocrine independence in breast cancer [ xref ]."
| PMC

sparser
"A virtual screen shows that the small molecule Imatinib could potentially interact with catalytic MPN domain of MYSM1 to inhibit BCa cell growth via MYSM1-ERα axis."